Rivera Fernández N1,2,
Mondragón Castelán M2,
González Pozos S3,
Ramírez Flores CJ2,
Mondragón González R4,
Gómez de León CT2,
Castro Elizalde KN2,
Marrero Ponce Y5,
Arán VJ6,
Martins Alho MA6,7,
Mondragón Flores R8.
Abstract
Quinoxalinone derivatives, identified as VAM2 compounds (7-nitroquinoxalin-2-ones), were evaluated against Toxoplasma gondii tachyzoites of the RH strain. The VAM2 compounds were previously synthesized based on the design obtained from an in silico prediction with the software TOMOCOMD-CARDD. From the ten VAM2 drugs tested, several showed a deleterious effect on tachyzoites. However, VAM2-2 showed the highest toxoplasmicidal activity generating a remarkable decrease in tachyzoite viability (in about 91 %) and a minimal alteration in the host cell. An evident inhibition of host cell invasion by tachyzoites previously treated with VAM2-2 was observed in a dose-dependent manner. In addition, remarkable alterations were observed in the pellicle parasite, such as swelling, roughness, and blebbing. Toxoplasma motility was inhibited, and subpellicular cytoskeleton integrity was altered, inducing a release of its components to the soluble fraction. VAM2-2 showed a clear and specific deleterious effect on tachyzoites viability, structural integrity, and invasive capabilities with limited effects in host cells morphology and viability. VAM2-2 minimum inhibitory concentration (MIC50) was determined as 3.3 μM ± 1.8. Effects of quinoxalinone derivatives on T. gondii provide the basis for a future therapeutical alternative in the treatment of toxoplasmosis.
KEYWORDS:
Apicomplexan; In silico drug design; Pellicle; Quinoxalinone derivatives; TOMOCOMD-CARDD; Toxoplasma gondii
- PMID:
- 26888289
- [PubMed - as supplied by publisher]
No comments:
Post a Comment